“
TL;DR
Twenty-five patients with biopsy-confirmed NASH underwent an oral 13C-octanoate breath test alongside IV 13C-glucose infusion to measure fasting endogenous glucose production.
Frontiers in Physiology · 7 authors, 5 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
Twenty-five patients with biopsy-confirmed NASH underwent an oral 13C-octanoate breath test alongside IV 13C-glucose infusion to measure fasting endogenous glucose production.
Twenty-five patients with biopsy-confirmed NASH underwent an oral 13C-octanoate breath test alongside IV 13C-glucose infusion to measure fasting endogenous glucose production. At baseline, subjects oxidized 23.4 ± 3.9% of the octanoate dose over 135 minutes, and octanoate oxidation was negatively correlated with fasting plasma glucose (r = −0.474, p = 0.017) and endogenous glucose production (r = −0.441, p = 0.028). Twenty-two subjects returned approximately 10 months later after lifestyle treatment or standard care; across all subjects, OctOx (% dose/kg) increased significantly (p = 0.044) and steatosis was reduced (p = 0.007). The authors conclude that octanoate breath testing warrants further study as a non-invasive indicator of liver fat and glucose metabolism in NASH.